These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16827720)

  • 1. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
    Itoh N; Kasai H; Ariyoshi W; Harada E; Yokota M; Nishihara T
    J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures.
    Otsuka T; Kasai H; Yamaguchi K; Nishihara T
    J Dent; 2005 Oct; 33(9):749-55. PubMed ID: 16199283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
    Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
    Murase Y; Okahashi N; Koseki T; Itoh K; Udagawa N; Hashimoto O; Sugino H; Noguchi T; Nishihara T
    J Cell Physiol; 2001 Aug; 188(2):236-42. PubMed ID: 11424090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
    Park EK; Kim MS; Lee SH; Kim KH; Park JY; Kim TH; Lee IS; Woo JT; Jung JC; Shin HI; Choi JY; Kim SY
    Biochem Biophys Res Commun; 2004 Dec; 325(4):1472-80. PubMed ID: 15555594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-myc is required for osteoclast differentiation.
    Battaglino R; Kim D; Fu J; Vaage B; Fu XY; Stashenko P
    J Bone Miner Res; 2002 May; 17(5):763-73. PubMed ID: 12009006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
    Uchiyama S; Yamaguchi M
    Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Murakami A; Aggarwal BB
    Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
    Woo JT; Nakagawa H; Krecic AM; Nagai K; Hamilton AD; Sebti SM; Stern PH
    Biochem Pharmacol; 2005 Jan; 69(1):87-95. PubMed ID: 15588717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
    Ishida M; Amano S
    J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
    Voronov I; Heersche JN; Casper RF; Tenenbaum HC; Manolson MF
    Biochem Pharmacol; 2005 Jul; 70(2):300-7. PubMed ID: 15919055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen-activated protein kinases mediate interleukin-1beta-induced receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells.
    Oikawa A; Kobayashi M; Okamatsu Y; Shinki T; Kamijo R; Yamamoto M; Hasegawa K
    J Periodontal Res; 2007 Aug; 42(4):367-76. PubMed ID: 17559635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts.
    Galli C; Macaluso GM; Guizzardi S; Vescovini R; Passeri M; Passeri G
    J Periodontol; 2006 Jul; 77(7):1223-8. PubMed ID: 16805686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
    Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways.
    Takami M; Cho ES; Lee SY; Kamijo R; Yim M
    FEBS Lett; 2005 Jan; 579(3):832-8. PubMed ID: 15670856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.